StemCell Therapy

SAN FRANCISCO, Aug. 31, 2020 /PRNewswire/ -- The global lab supplies marketsize is expected to reach USD 49.6 billion by 2027, expanding at a CAGR of7.1%,according to a new report by Grand View Research, Inc. Focus on R&D drives the demand for lab equipment market, thereby boosting the market growth.

In June 2019, the D.O.D's Defense Logistics Agency settled the bidding process for USD 312.0 million contracts, for lab equipment and supplies. There are instances of huge government spending in the category including White House's budget of 2020 that provides USD 134.0 billion for federal R&D, including significant investments in R&D facilities and equipment.

Key suggestions from the report:

Read 120 page research report with ToC on "Lab Supplies Market Size, Share & Trends Analysis Report By Product (Equipment (Autoclaves & Sterilizers, Lab Air Filtration System), Disposables (Tubes, Gloves)), By Region, And Segment Forecasts, 2020 - 2027" at: https://www.grandviewresearch.com/industry-analysis/laboratory-supply-market

Laboratories have emerged as multipurpose research facilities in which various types of testing mechanisms, research analogies, and novel developments are carried out. This has also led to an increase in the demand for lab equipment and supplies market. Furthermore, the trend of research-based studies has been gaining traction over the past decade. This has resulted in the development of new laboratories in academic institutes, thereby boosting the market growth.

Recently, clinical laboratories have also gone through major technological advancements. With intense R&D going in the field of the pathogenesis of diseases and personalized medicine, advanced diagnostics methods and tests are being implemented extensively. Technological improvements in instrumentation continue to bring real benefits that accrue from greater ease of use, increased capacity, speed of analysis, higher precision, operational efficiencies, enhanced reliability, improved safety, and numerous other intangibles.

Grand View Research has segmented the global lab supplies market based on product and region:

Find more research reports on Medical Devices Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected] Web:https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Follow this link:
Lab Supplies Market Size Worth $49.6 Billion By 2027 | CAGR: 7.1%: Grand View Research, Inc. - PRNewswire

Patients across the Valley will soon feel more connected to their healthcare providers thanks to a mobile app changing the way clinical documentation and data entry are performed. Bayless Integrated Healthcare, an Arizona leader in integrating mental and physical health, has announced a partnership with Seattle-based healthcare technology company, Saykara, to implement this new technology in its eight locations across the Phoenix area.

The amount of data entry providers must do is on the rise due to additional requirements from insurance companies and government agencies. During a typical appointment, providers must simultaneously converse with patients while filling out electronic health records on a computer, which creates the feeling that providers are disengaged and multi-tasking, rather than offering their full attention. The data entry workload can be so great that providers often bring it home to complete during evening hours, contributing to fatigue and burnout.

The technology from Saykara reverses this trend by utilizing artificial intelligence to automate the challenging and time-consuming aspects of clinical documentation. This frees providers from their computers and restores quality facetime with patients.

Whole person wellness defines everything that we do at Bayless, says President and CEO of Bayless Integrated Healthcare, Justin Bayless. We know that the patient/provider connection is a deeply important part of that equation, and we continuously invest in the tools and technologies to improve that relationship. The more our patients feel heard during their appointments, and the more focused our providers are on them rather than data entry, the better our delivery of personalized medicine and the better our patient outcomes.

At the start of an appointment and with the patients consent, the Bayless provider simply accesses the Saykara mobile app from their iPhone. As the provider and patient engage, the app interprets the conversation and translates it to the data required for the electronic health record, reducing administrative busywork down to mere minutes, rather than hours.

Nobody wants to feel like theyre taking a back seat to administrative busywork when visiting a healthcare provider. This is when were all at our most vulnerable, says President and COO of Saykara, Graham Hughes, MD. By automating clinical documentation, our technology helps ensure that the time shared between a patient and provider is undistracted and that a trusting bond is forged.

The introduction of this technology at Bayless comes at a time when healthcare providers are increasingly reporting burnout amid the COVID-19 pandemic and may help alleviate some of the pressures they face. The result is reduced fatigue in providers, increased facetime with patients and a more trusting and deeply connected relationship between providers and the people in their care.

See the article here:
Bayless Integrated Healthcare deploys AI to improve patient care - AZ Big Media

Background:Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available.

Methods:The study is a prospective, phase III, controlled, multicenter, and randomized, single-blind (patient) clinical trial, including RA patients with a previous failure to anti-TNF therapies. The main objective is the analysis of the clinical and pharmacoeconomic impact after 6 months of treatment. Intervention arm: prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest software, a prediction software based on proteomic biomarkers. Control arm: prescription of biotherapy based on current practice, without the SinnoTest software (any biotherapy). In addition, a substudy will be carried out within this trial to generate a biobank and further analyze the proteomic profile of the patients and their modification throughout the study.

Discussion:This clinical trial study will be the first validation study of a biotherapy response prediction software, bringing personalized medicine into the management of RA. We expect that the findings from this study will bring several benefits for the patient and the Health Care System.

Trial registration:ClincalTrials.govNCT04147026. Registered on 31 October, 2019.

Keywords:Anti-TNF agents; Personalized medicine; Prediction models; Rheumatoid arthritis.

View original post here:
Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response...

~Program to Focus on Advances and Breakthroughs in MS Research, Diagnostics and Technology~

~Special Press Events Planned to Give Media Access to Key Leaders & Late Breaker Investigators~

MIDDLETON, Wis., Aug. 31, 2020 /PRNewswire/ -- The 8th Joint ACTRIMS-ECTRIMS Meeting, the largest international conference focused on Multiple Sclerosis (MS) research, will be held in a virtual format from September 11-13, 2020, with a special encore session featuring Late-Breaking News and a COVID-19 Session on September 26.

At this virtual conference MSVirtual2020 world class scientists, neurologists, clinicians and researchers from around the world will be presenting the latest research, clinical trial outcomes and technology and diagnostic advances in multiple sclerosis (MS).

Media registration, which is open to editors, reporters, producers, and active freelance writers and bloggers, will allow access to the full program including plenary sessions, invited speakers and platform presentations. Press Registration can be completed online here, or to expedite press registration, you can send a request directly to the Press Managers. They can be reached at: [emailprotected]and [emailprotected]. They are also available to arrange interviews with participating leaders, presenters and experts that you may wish to connect with.

The MSVirtual2020 program at a glance can be found here. Key topics will cover:

Keynote speakers will include:

MSVirtual2020 will be hosting a Newsroom on Newswise that will house various media materials including press releases, videos, infographics, bios & photos of leaders and speakers, and other assets. Newswise will also host a few Zoom press events for media only that will allow registered journalists to access and ask live questions to ACTRIMS-ECTRIMS leaders and late breaking investigators. The link to the MSVirtual2020 Newsroom is: here, or at the following link: https://www.newswise.com/home/actrims. The conference hashtag is: #MSVirtual2020.

MSVirtual2020 Press Events:

SOURCE Americas Committee for Treatment and Research in Multiple Sclerosis

Read more here:
The 8th Joint ACTRIMS-ECTRIMS Meeting - MSVirtual2020 - To be Held September 11-13 With A Special Encore Session Featuring COVID-19 & MS and Late...

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Peloton (NASDAQ: PTON), the world's largest interactive fitness platform, today announced the formation of the Peloton Health and Wellness Advisory Council, which will work closely with the company as it continues to look at how it can positively impact the physical, mental and emotional wellbeing of its community of Members from around the world. Peloton will collaborate with the council, which includes five renowned doctors, researchers and other medical professionals from the fields of cardiovascular medicine, cardiopulmonary exercise, neurology and neuroscience, and draw on their knowledge and expertise to help inform product and content development, community-focused and social impact initiatives, research projects and more.

"We constantly hear from our Members that Peloton has not only profoundly impacted their physical, mental and emotional health, but has also helped them cope with issues ranging from neurodegenerative disease or cancer, to PTSD or post-partum depression," said William Lynch, president, Peloton. "With the addition of this esteemed Health and Wellness Advisory Council, which includes some of the best minds in medicine, we can leverage scientific research and medical expertise to help us better serve our community through our content, products and platform."

The Peloton Health and Wellness Advisory Council includes the following experts:

Cardiovascular MedicineSuzanne Steinbaum, MD:Dr. Suzanne Steinbaum is an attending cardiologist, specializing in prevention. She has recently opened a private practice in New York City, at the Juhi-Ash integrative health center encompassing heart health, wellness and prevention, as well as the effects of stress and inflammation on heart health. She is the founder and President of SRSHeart, a personalized lifestyle management program using anatomy, physiology, functional data, genetics and metabolism, along with technology to reach ultimate cardiovascular health. She has been the Director of Women's Cardiovascular Prevention, Health and Wellness at Mt. Sinai Heart in New York City, after being the Director of Women's Heart Health at Northwell Lenox Hill. Dr. Steinbaum is a Fellow of the American College of Cardiology and the American Heart Association. She is a National Spokesperson for the Go Red for Women campaign and chairperson of the Go Red for Women in New York City. She is on the New York City Board of the American Heart Association and on the Scientific Advisory Board of the Women's Heart Alliance.

NeurologyRichard S. Isaacson, MD:Richard S. Isaacson, M.D. is a Neurologist, clinician and researcher who specializes in Alzheimer's prevention and treatment. He previously served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. Prior to joining UM, he served as Associate Medical Director of the Wien Center for Alzheimer's disease and Memory Disorders at Mount Sinai. Dr. Isaacson specializes in Alzheimer's disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and preclinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia is an important strategy for optimizing cognitive function and reducing risk of dementia. He has also published novel methods on using a precision medicine approach in real-world clinical practice. He has also led the development of Alzheimer's Universe (AlzU.org) a vast online education research portal on AD with results published in the Journal of the Prevention of Alzheimer's disease, Journal of Communication in Healthcare, Alzheimer's & Dementia: Translational Research & Clinical Interventions, and Neurology. With a robust clinical practice and broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and lifestyle interventions (such as physical exercise and nutrition) to optimize patient care, AD risk assessment and early intervention.

Vernon Williams, MD:Vernon Williams, MD is the Founding Director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, CA. Dr. Williams is a former Commissioner for the California State Athletic Commission and current Chair of Neurological Health for the Commission's Medical Advisory Committee, as well as a former two-term Chair of the American Academy of Neurology Sports Neurology Section. He serves as a neurological medical consultant to local professional sports organizations such as the Los Angeles Rams, Los Angeles Dodgers, Los Angeles Lakers, Los Angeles Kings and Los Angeles Sparks. He also assists local colleges and numerous high school and youth sports/club athletic teams in this capacity. Dr. Williams is a board-certified clinical neurologist with very specialized areas of subspecialty: Sports Neurology and Pain Medicine. He is actively engaged in researching and developing innovative and effective treatments and technologies that help people recognize symptoms of a neurological injury sooner so that the work of treating them can happen faster, and with less potential for permanent damage. He passionately advocates for optimization of Neurological Health across the lifespan for his patients and peak performance clients.

Cardiopulmonary ExerciseAimee M. Layton, PhD:Aimee Layton, PhD is an Assistant Professor of Applied Physiology in Pediatrics in the Division of Pediatric Cardiology and the Director of the Pediatric Cardiopulmonary Exercise Laboratory at Columbia University Medical Center / New York Presbyterian Hospital. Dr. Layton recently joined the pediatric cardiology team after being director of the adult pulmonary exercise laboratory for a decade. This cross discipline experience provides Dr. Layton with knowledge of both how the lungs and the heart respond to exercise and the role of disease and sports in both adults and kids. Dr. Layton's prior research investigated respiratory biomechanics, with publications in both diseased and healthy populations. Her new research focuses on bridging the gap between the lab and the home, in hopes of impacting kids' behavior and relationship with exercise. Dr. Layton is a respected expert in clinical exercise physiology and has lectured internationally on the topic. Beyond her research, Dr. Layton has been performing exercise testing and counseling for both patients with lung disease and patients with heart disease. She plays an important role as one of the lead exercise physiologists for Columbia University Medical Center in testing, exercise counseling and research.

NeuroscienceJay Alberts, PhD:As a Cleveland Clinic Scientist, Ph.D., Jay Alberts' research is aimed at understanding the structure-function relationships within the central nervous system and evaluating the impact of behavioral and surgical interventions to improve motor and non-motor function in Parkinson's disease, stroke, Alzheimer's and other neurological populations. Human studies are currently ongoing to address these basic and translational research questions. Dr. Alberts is developing and validating new methods of using exercise and augmented and virtual reality to engage patient populations remotely. He is currently leading two multi-site clinical trials investigating the role of exercise in slowing the progression of Parkinson's disease. Dr. Alberts has led multiple successful technology initiatives aimed at better understanding patient symptoms and communicating these symptoms to providers. He is currently building AR and VR applications as prescriptive digital therapeutic systems for neurological patients. To date, Dr. Alberts has written 100 peer reviewed articles, has had uninterrupted extramural funding since 1999 and holds 10 patents.

For more information about Peloton or the Peloton Health and Wellness Advisory Council, please visit http://www.blog.onepeloton.com.

About PelotonPeloton is the largest interactive fitness platform in the world with a loyal community of more than 2.6 million Members. The company pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its Members anytime, anywhere. Peloton makes fitness entertaining, approachable, effective, and convenient, while fostering social connections that encourage its Members to be the best versions of themselves. An innovator at the nexus of fitness, technology, and media, Peloton has reinvented the fitness industry by developing a first-of-its-kind subscription platform that seamlessly combines the best equipment, proprietary networked software, and world-class streaming digital fitness and wellness content, creating a product that its Members love. The brand's immersive content is accessible through the Peloton Bike, Peloton Tread, and Peloton App, which allows access to a full slate of fitness classes across disciplines, on any iOS or Android device, Apple TV, Fire TV, Roku TVs, and Chromecast and Android TV. Founded in 2012 and headquartered in New York City, Peloton has a growing number of retail showrooms across the US, UK, Canada and Germany. For more information, visit http://www.onepeloton.com.

SOURCE Peloton

http://www.pelotoncycle.com

More:
Peloton Introduces Its First-Ever Health And Wellness Advisory Council - PRNewswire

EAGAN, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor Conference, on Wednesday, September 02, 2020 3:40 PM Eastern Time.

A live webcast of the presentation will be available to the public at https://www.webcaster4.com/Webcast/Page/2019/36691. The webcast will be archived for 90 days following the live presentation.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.Predictive-Oncology.com.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate,” believe,” estimate,” expect,” intend,” may,” plan,” would,” target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IR James Carbonara (646)-755-7412 james@haydenir.com

Read the original post:
Predictive Oncology Inc to Present at LD Micro's "LD 500" Virtual Investor Conference on Wednesday, September 02, 2020 3:40 PM Eastern Time...

Precision Medicine Market Trends, In-Depth Research on Market Size, Emerging Growth Factors, Global 2020 Trends and Forecasts 2025

The Precision MedicineMarket report is one of the most comprehensive and important dataabout business strategies, qualitative and quantitative analysis of Global Market.It offers detailed research and analysis of key aspects of the Precision Medicinemarket. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Precision Medicinemarket.

The researchers have considered almost all important parameters for company profiling, including market share, recent development, gross margin, future development plans, product portfolio, production, and revenue. The report includes detailed analysis of the vendor landscape and thorough company profiling of leading players of the Precision Medicine market.

Get PDF sample copy of this report(Including impact of Covid-19)@: https://www.marketinforeports.com/Market-Reports/Request-Sample/161616

Top Leading players covered in the Precision Medicine market report: Johnson & Johnson, IBM, GE Healthcare, Illumina, Roche, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Novartis, Abbott Laboratories, Almac Group, Intel Corporation, Biomrieux Sa, Cepheid, Qiagen, Randox Laboratories, Healthcore and More

Key Types:DiagnosticsTherapies

Key End-Use:OncologyNeurosciencesImmunologyRespiratoryOthers

The global Precision Medicine market is analyzed across key geographies namely: North America, Europe, Asia-Pacific, South America, Middle East and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

The latest report added by Market Info Reportsdemonstrates that the global Precision Medicine market will showcase a steady CAGR in the coming years. The research report includes a thorough analysis of market drivers, restraints, threats, and opportunities. It addresses the lucrative investment options for the players in the coming years. Analysts have offered market estimates at a global and regional level.

Major Points Covered in TOC:

Overview: Along with a broad overview of the global Precision Medicine market, this section gives an overview of the report to give an idea about the nature and contents of the research study.

Analysis on Strategies of Leading Players: Market players can use this analysis to gain competitive advantage over their competitors in the Precision Medicine market.

Study on Key Market Trends: This section of the report offers deeper analysis of latest and future trends of the Precision Medicine market.

Market Forecasts: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Precision Medicine market.

Regional Growth Analysis: All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis: The report provides accurate and reliable forecasts of the market share of important segments of the Precision Medicine market. Market participants can use this analysis to make strategic investments in key growth pockets of the Precision Medicine market.

For More Information:https://www.marketinforeports.com/Market-Reports/161616/Precision-Medicine-market

The study objectives are:

Customization of the Report:

Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/161616/Precision-Medicine-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]

Original post:
Precision Medicine Market Analysis By Distribution Channel, Region And Forecast From 2020 To 2025|Johnson & Johnson, IBM, GE Healthcare, Illumina,...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Precision Medicine market.

Trusted Business Insights presents an updated and Latest Study on Precision Medicine Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Precision Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Precision Medicine MarketIndustry / Sector Trends

Precision Medicine Market size was valued at USD 52.6 billion in 2018 and is expected to witness 10.5% CAGR from 2019 to 2025.

U.S.Market Segmentation, Outlook & Regional Insights: Precision Medicine Market

Precision Medicine Market, By Technology, 2018 & 2025 (USD Million)

Growing demand and advancements in cancer biology will drive personalized medicine market during the forecast period. Accessibility to large-scale human genome database including next-generation sequencing (NGS) and computational tools foster industry growth. Development of innovative genetic technologies examines the functional effect of genetic makeup that leads in developing cancer, thus, should propel huge demand for cancer biology. Several such tools are widely used to study the mechanism of DNA repair, epigenetic changes related to cancer and gene regulation in cancerous cells that offer opportunities for cancer biology in personalized medicine.

Moreover, improving efficiencies within the health care system will serve to be positive impact rendering factor personalized treatment business growth. Benefits offered by personalized medicines and treatment includes target treatment for patient, optimal dosing, focus on prevention and earlier intervention as well as preventing adverse events. Thus, above mentioned features will foster the demand for personalized medication market growth. However, high cost associated with precision medicine may impede industry growth over the forecast period.

Precision Medicine Market, By Technology

Drug discovery segment held over 21% revenue share in 2018 and is projected to grow significantly by 2025. Focus of business players on developing technologically advanced drugs enabling superior treatment for several life-threatening diseases will create segmental growth opportunities. Bio-pharmaceutical companies utilize bioinformatics software to introduce customized novel drugs that should augment the segmental growth.

Gene sequencing segment is anticipated to show exponential CAGR of around 11% over the coming years. Benefits offered by gene sequencing technique such as relevant information about patients genome and biological research ensures quick drug discovery process that should boost segmental growth.

Precision Medicine Market, By Application

Immunology segment accounted for over USD 9.5 billion in 2018 and is estimated to witness considerable growth trend during the analysis period. Growing demand for bioinformatics and big data analytics to segregate human genome data obtained from immunological processes favors segmental growth.

Oncology segment held significant revenue share in 2018 and is assessed to show more than 10.5% CAGR during the forecast period. Segment growth is attributable to increasing prevalence of cancer cases resulting in development of innovative drugs with specific drug formulations in precision medicine.

Germany Precision Medicine Market Size, By Application, 2018 (USD Million)

Precision Medicine Market, By End-use

Healthcare IT companies segment held more than 27% revenue share in 2018 and will show lucrative growth over coming years. Increasing demand for developing technologically advanced tools for rapid integration, storage, and analysis of patient data should augment the business growth.

Diagnostic companies segment was valued around USD 9.5 billion in 2018. Such companies provide solutions that bridges the gap between clinical needs of patients and technology. Various benefits such as high quality of the medical diagnostic devices enabling precise patient management will foster industry growth.

Precision Medicine Market, By Region

North America precision medicine market is predictable to show around 9% CAGR over the analysis period. Rising prevalence of respiratory and oncology diseases as a result of lifestyle changes is the key factor driving demand for market. Rising healthcare expenditure coupled with presence of major industry players in North America will spur the business growth.

Asia Pacific precision medicine industry was valued more than USD 11 billion revenue in 2018. Regional growth can be attributed to technological advances in sequencing technology. Moreover, presence of large patient pool in Asia Pacific along with growing investments in R&D activities will accelerate personalized medication business growth.

MEA Precision Medicine Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Precision Medicine Market

Few of the prominent industry players operating in precision medicine industry include Biocrates Life Sciences, Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Novartis, NanoString Technologies, Pfizer, Eagle Genomics, Quest Diagnostics, Roche, Intomics, and Teva Pharmaceutical. The business players implement several strategies including acquisitions, partnerships and innovative product enhancement to capitalize on market growth opportunities.

Recent industry developments:

In October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle computational challenges of genomics era. This partnership aimed to inculcate scale and power of cloud to precision medicine, across the production of fundamental research and core services.

In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine to more patients.

Precision Medicine Industry Viewpoint

History of precision medicine can be tracked back in 1950s when Watson and Crick discovered the structure of the DNA as double-helix. Efforts to supplement the DNA structure, researchers cracked the genetic code in early 1960s. Additionally, introduction of the first DNA sequencing technology was developed in 1970s where researchers discovered first enzyme linked to individual variation in response to dosing. In early 1980s Polymerase Chain Reaction (PCR) was first discovered allowing for fast amplification of DNA sequences. These advances continued in 1990s where human genome project was launched along with FDA approval for first personalized medicine with a companion diagnostic, for the treatment of HER2 positive breast cancer. Such form of advancements continued in 2000s where first targeted therapies for lung cancer, leukemia, melanoma, cystic fibrosis, HIV, and other diseases accelerated tremendous growth opportunities for precision medicine. Moreover, increasing demand for personalized medication for secured patient management will drive industry growth during the forthcoming years

Key Insights Covered: Exhaustive Precision Medicine Market1. Market size (sales, revenue and growth rate) of Precision Medicine industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Precision Medicine industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Precision Medicine industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Precision Medicine industry.

Research Methodology: Precision Medicine Market

Looking for more? Check out our repository for all available reports on Precision Medicine in related sectors.

Quick Read Table of Contents of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more:
Precision Medicine Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 - The Scarlet